Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC cut its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 62.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,995 shares of the company’s stock after selling 16,836 shares during the period. Calamos Advisors LLC’s holdings in Vaxcyte were worth $818,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PCVX. Riverview Trust Co acquired a new stake in shares of Vaxcyte during the third quarter valued at about $27,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. acquired a new stake in shares of Vaxcyte during the third quarter valued at about $92,000. Finally, Signaturefd LLC increased its position in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after acquiring an additional 358 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,735,022.90. This represents a 3.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 68,616 shares of company stock worth $6,095,681 in the last 90 days. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Stock Up 3.3 %

NASDAQ PCVX opened at $89.34 on Thursday. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The stock has a market capitalization of $11.14 billion, a PE ratio of -19.42 and a beta of 0.98. The firm has a 50 day moving average of $87.37 and a two-hundred day moving average of $94.45.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the firm posted ($0.91) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PCVX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average price target of $145.71.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.